Tacrolimus (tacrolimus elimination)

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Southern Medical University, China

Conditions

Liver Transplant RecipientLiver Transplantation

Phase 2

Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation

Southern Medical University, ChinaLiver Transplantation

Start: 2018-05-01End: 2023-05-31Target: 130Updated: 2018-04-18

Phase 3

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

CompletedNCT00622869

Novartis PharmaceuticalsLiver Transplantation

Start: 2008-01-31End: 2012-04-30Updated: 2013-05-27

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

CompletedNCT01150097

Novartis PharmaceuticalsLiver Transplant Recipient

Start: 2010-03-31End: 2013-05-03Updated: 2018-11-07

Related Papers

Everolimus Impact On Hepatocellular Carcinoma Recurrence After Liver Transplantation - 12, 24, and 36 Months Data From 719 Liver Transplant Recipients.

Transplantation2014-07-016 citations

Efficacy and Safety of Everolimus With Reduced Tacrolimus in De Novo Liver Transplant Recipients: Long-Term Results From the H2304E1 Study.

Transplantation2014-07-013 citations

Long-Term Safety With Everolimus-Based Regimen in De Novo Liver Transplant Recipients: 4-Year Results From The Extension of H2304 Study.

Transplantation2014-07-01

mTOR inhibition in liver transplantation: how to dose for effective/safe CNI reduction?

2013-06-012 citations